



1600

0500

TECH CENTER 1600/2900

6
4/11/02
82
RECEIVED
MAR 19 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
Application of: Himmelsbach et al.
Serial No.: 09/914,323 ✓
Filing Date: 08/24/2001
Title: 4-AMINO-QUINAZOLINE AND QUINOLINE
DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL
TRANSDUCTION MEDIATED BY TYROSINE KINASES ✓
Docket No.: 5/1252

Commissioner for Patents
Washington, D.C. 20231

October 19, 2001

**TRANSMITTAL LETTER FOR
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:


Transmitted herewith concerning the subject application is an Information Disclosure Statement under 37 C.F.R. §§1.56, copy of International Search Report and

☒ 1.97(b). This Statement is being filed within three months of the filing date of a national application; within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; or before the mailing of a first Office Action on the merits, whichever event occurs last.

☒ The Assistant Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.


Respectfully submitted,


Alan R. Stempel
Attorney for Applicant(s)
Reg. No. 28,991

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road, P.O. Box 368
Ridgefield, CT. 06877
Tel.: (203) 798-4868

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as express mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, DC 20231

on October 19, 2001

By: Alan R. Stempel, Reg. No. 28,991